040 Th/Tc9 and Th/Tc17 Pathways Are Augmented in Moderate-To-Extensive Bullous Pemphigoid Patients and Suppressed by Bertilimumab

Journal of Investigative Dermatology - United Kingdom
doi 10.1016/j.jid.2019.03.116
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Orphan Designation: Bertilimumab, Treatment of Bullous Pemphigoid

Case Medical Research
2018English

Doxycycline and the Treatment for Bullous Pemphigoid: What Outcomes Are Most Important to Our Patients?

British Journal of Dermatology
DermatologyMedicine
2017English

Bullous Pemphigoid

2020English

Th-1, Th-2 Cytokines Profile Among Madurella Mycetomatis Eumycetoma Patients

PLoS Neglected Tropical Diseases
PharmacologyPublic HealthEnvironmentalToxicologyInfectious DiseasesPharmaceuticsOccupational Health
2016English

Circulating CD4+ CD25brightFOXP3+ Regulatory T-Cells Are Significantly Reduced in Bullous Pemphigoid Patients

Archives of Dermatological Research
DermatologyMedicine
2012English

Advances in Understanding and Managing Bullous Pemphigoid

F1000Research
GeneticsMolecular BiologyPharmacologyBiochemistryMicrobiology ImmunologyMedicineToxicologyPharmaceutics
2015English

570 Safety and Efficacy of Bertilimumab, a Human Anti-Eotaxin-1 Monoclonal Antibody, in Bullous Pemphigoid in a Phase 2a Study

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Diagnosis of Bullous Pemphigoid by Haematoxylin and Eosin Staining

International Journal of Clinical & Medical Imaging
2017English

Carbamazepine-Induced Bullous Eruption or Bullous Pemphigoid?

Postgraduate Medical Journal
Medicine
1984English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy